While not always a complete disqualifier, patients who have a history of the following conditions should likely avoid Semaglutide: Multiple endocrine neoplasia syndrome type 2 (MEN2) Pancreatitis Gallbladder problems Thyroid cancer Type I diabetes History of severe symptoms of low blood sugar If a patient currently takes a GLP-1 medication, they may be able to switch to Semaglutide
As a dual incretin receptor agonist, tirzepatide serves as a research tool for multi-target receptor signaling in metabolic regulation
Im a little nervous about weight regain, but Im certainly more mindful and appreciative of my lifestyle changes
Very easy to administer, instructions are great and it works
In weight management, tirzepatide (Zepbound) addresses a significant need for effective pharmacotherapy in obesity treatment
Semaglutide targets the GLP-1 hormone, while tirzepatide targets both GLP-1 and GIP